DelveInsight’s, “IgA Nephropathy Pipeline Insight 2023” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy pipeline drug profiles, including IgA Nephropathy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the IgA Nephropathy Pipeline Report
Request a sample and discover the recent breakthroughs happening in the IgA Nephropathy Pipeline landscape @ IgA Nephropathy Pipeline Outlook Report
IgA Nephropathy Overview
IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses.
Recent Developmental Activities in the IgA Nephropathy Treatment Landscape
For further information, refer to the detailed IgA Nephropathy Drugs Launch, W IgA Nephropathy Developmental Activities, and IgA Nephropathy News, click here for IgA Nephropathy Ongoing Clinical Trial Analysis
IgA Nephropathy Emerging Drugs Profile
Atrasentan is a potent and selective, small molecule inhibitor of the endothelin A receptor for the potential treatment of IgA Nephropathy (IgAN) and other proteinuric glomerular diseases. Chinook Therapeutics has initiated a phase III trial (ALIGN) of Atrasentan in early 2021 in patients with IgAN at high risk of kidney function decline.
Sparsentan is a novel small-molecule candidate in Phase III development for the treatment of IgA nephropathy (IgAN). IgAN, also called Berger’s disease, is a type of glomerulonephritis. Sparsentan is a single molecule designed to selectively block the receptors of two pathways which are associated with kidney disease progression. The receptors are endothelin 1A and angiotensin II type 1. In March 2022, Travere Therapeutics, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).
IgA Nephropathy Pipeline Therapeutics Assessment
There are approx. 30+ key companies which are developing the therapies for IgA Nephropathy. The companies which have their IgA Nephropathy drug candidates in the most advanced stage, i.e. Preregistration include, Travere Therapeutics.
Find out more about the IgA Nephropathy Pipeline Segmentation, Therapeutics Assessment, and IgA Nephropathy Emerging Drugs @ IgA Nephropathy Treatment Landscape
Scope of the IgA Nephropathy Pipeline Report
Dive deep into rich insights for drugs for IgA Nephropathy Pipeline Companies and Therapies, click here @ IgA Nephropathy Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on IgA Nephropathy Mergers and acquisitions, IgA Nephropathy Licensing Activities @ IgA Nephropathy Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/